SOPH Stock Forecast 2025-2026
Distance to SOPH Price Targets
SOPH Price Momentum
🤔 Considering SOPHiA GENETICS (SOPH)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest SOPH Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, SOPH has a bullish consensus with a median price target of $6.00 (ranging from $5.00 to $11.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $3.22, the median forecast implies a 86.3% upside. This outlook is supported by 5 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Rich Hilliker at Credit Suisse, suggesting a 55.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SOPH Analyst Ratings
SOPH Price Target Range
Latest SOPH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SOPH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 18, 2024 | Craig-Hallum | Buy | Initiates | $11.00 | |
| Aug 7, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $7.00 |
| Jun 27, 2024 | Guggenheim | Subbu Nambi | Buy | Initiates | $6.00 |
| Mar 6, 2024 | BTIG | Mark Massaro | Buy | Maintains | $8.00 |
| Mar 6, 2024 | RBC Capital | Conor McNamara | Outperform | Reiterates | $8.00 |
| Jan 12, 2024 | RBC Capital | Conor McNamara | Outperform | Reiterates | $8.00 |
| Nov 29, 2023 | RBC Capital | Conor McNamara | Outperform | Initiates | $8.00 |
| May 10, 2023 | Credit Suisse | Rich Hilliker | Neutral | Maintains | $5.00 |
| May 10, 2023 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $10.00 |
| Mar 8, 2023 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $11.00 |
| Jan 3, 2023 | BTIG | Mark Massaro | Buy | Initiates | $6.00 |
| Nov 23, 2022 | Credit Suisse | Phil Winslow | Neutral | Initiates | $2.00 |
| Nov 9, 2022 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $12.00 |
| Aug 10, 2022 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $13.00 |
| May 11, 2022 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $14.00 |
| Mar 16, 2022 | Morgan Stanley | Overweight | Maintains | $17.00 | |
| Feb 15, 2022 | Morgan Stanley | Overweight | Maintains | $18.00 | |
| Aug 17, 2021 | JP Morgan | Overweight | Initiates | $0.00 | |
| Aug 17, 2021 | Cowen & Co. | Outperform | Initiates | $0.00 | |
| Aug 17, 2021 | Morgan Stanley | Overweight | Initiates | $0.00 |
Sophia Genetics SA (SOPH) Competitors
The following stocks are similar to SOPHiA GENETICS based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Sophia Genetics SA (SOPH) Financial Data
Sophia Genetics SA has a market capitalization of $215.20M with a P/E ratio of -3.4x. The company generates $65.17M in trailing twelve-month revenue with a -95.9% profit margin.
Revenue growth is +4.0% quarter-over-quarter, while maintaining an operating margin of -98.4% and return on equity of -50.4%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Sophia Genetics SA (SOPH) Business Model
About Sophia Genetics SA
Provides AI-driven data analytics for healthcare.
The company operates by offering a platform that integrates diverse medical data to enhance clinical diagnosis and treatment personalization. It generates revenue by providing data interpretation solutions to healthcare institutions in sectors like oncology and cardiology, thereby facilitating improved patient outcomes through actionable insights.
Founded in 2011, Sophia Genetics aims to democratize data-driven medicine, ensuring data standardization and accessibility across global healthcare networks. Its contributions significantly advance the field of precision medicine, making it a key player in healthcare innovation.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
423
CEO
Dr. Jurgi Camblong M.B.A., Ph.D.
Country
Switzerland
IPO Year
2021
Website
www.sophiagenetics.comSophia Genetics SA (SOPH) Latest News & Analysis
SOPHiA GENETICS SA will hold its Q4 2024 earnings call on March 4, 2025, at 8:00 AM ET, featuring key executives and analysts from Guggenheim, BTIG, Morgan Stanley, and Craig-Hallum.
SOPHiA GENETICS' earnings call indicates upcoming financial disclosures that could impact stock performance, revealing insights on growth, strategy, and market outlook.
SOPHiA GENETICS reported Q4 2024 revenue of $17.7M, up 4% YoY, with a gross margin of 68.2%. Full year revenue was $65.2M, also up 4%. Operating losses improved year-over-year.
SOPHiA GENETICS shows modest revenue growth and improving gross margins, signaling operational efficiency. However, ongoing losses may concern investors regarding future profitability amidst industry challenges.
SOPHiA GENETICS SA reported a quarterly loss of $0.23 per share, slightly better than the expected loss of $0.24, and an improvement from a loss of $0.37 per share a year prior.
SOPHiA GENETICS' smaller-than-expected loss may indicate improving financial performance, potentially boosting investor confidence and affecting stock valuation.
SOPHiA GENETICS (Nasdaq: SOPH) announced the global adoption of its cancer testing applications by 37 leading institutions, enhancing its position in AI healthcare and oncology testing.
SOPHiA GENETICS' expansion in oncology testing with major institutions enhances its market position and growth potential, signaling increased demand for its AI-driven healthcare solutions.
SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2024 on March 4, 2025
26 days agoSOPHiA GENETICS (Nasdaq: SOPH) will release its Q4 and full year 2024 financial results on March 4, 2025, before market open, followed by a conference call at 8:00 a.m. ET.
SOPHiA GENETICS' upcoming financial results release and conference call could impact stock performance, providing insights into its growth and future business strategies.
SOPHiA GENETICS launched the OncoPortal™ Mutation Tracker, a tool for monitoring evolving genomic cancer drivers, enhancing precision in oncology disease management.
The launch of the OncoPortal™ Mutation Tracker positions SOPHiA GENETICS as a leader in cancer monitoring, potentially increasing market share and attracting investment due to innovative healthcare solutions.
Frequently Asked Questions About SOPH Stock
What is Sophia Genetics SA's (SOPH) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Sophia Genetics SA (SOPH) has a median price target of $6.00. The highest price target is $11.00 and the lowest is $5.00.
Is SOPH stock a good investment in 2025?
According to current analyst ratings, SOPH has 5 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.22. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SOPH stock?
Wall Street analysts predict SOPH stock could reach $6.00 in the next 12 months. This represents a 86.3% increase from the current price of $3.22. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Sophia Genetics SA's business model?
The company operates by offering a platform that integrates diverse medical data to enhance clinical diagnosis and treatment personalization. It generates revenue by providing data interpretation solutions to healthcare institutions in sectors like oncology and cardiology, thereby facilitating improved patient outcomes through actionable insights.
What is the highest forecasted price for SOPH Sophia Genetics SA?
Price targets from Wall Street analysts for SOPH are not currently available. The stock is trading at $3.22.
What is the lowest forecasted price for SOPH Sophia Genetics SA?
The lowest price target for SOPH is $5.00 from Rich Hilliker at Credit Suisse, which represents a 55.3% increase from the current price of $3.22.
What is the overall SOPH consensus from analysts for Sophia Genetics SA?
The overall analyst consensus for SOPH is bullish. Out of 7 Wall Street analysts, 5 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $6.00.
How accurate are SOPH stock price projections?
Stock price projections, including those for Sophia Genetics SA, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
